VTYX — Ventyx Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00
- $314.81m
- $62.59m
- 31
- 28
- 13
- 13
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -4.33 | -28.2 | -83.7 | -108 | -193 |
Depreciation | |||||
Non-Cash Items | 1.09 | 21.2 | 41 | 14.7 | 20.5 |
Unusual Items | |||||
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.591 | 0.812 | 4.02 | -5.16 | 5.81 |
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Cash from Operating Activities | -2.64 | -6.2 | -38.6 | -98.8 | -167 |
Capital Expenditures | 0 | 0 | -0.262 | -0.275 | -0.514 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 0 | 0 | -214 | -74.7 | 101 |
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 0 | 0 | -214 | -74.9 | 101 |
Financing Cash Flow Items | 0 | 6.13 | 0.45 | 0.267 | 0.25 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 2.95 | 6.13 | 324 | 168 | 53.3 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.309 | -0.065 | 70.5 | -5.97 | -12.3 |